25 May 2022

Atezolizumab with bevacizumab for patients with resected or ablated hepatocellular carcinoma who are at high risk for disease recurrence

Atezolizumab and bevacizumab in combination is in clinical development for treating adults with high risk of hepatocellular carcinoma (HCC) coming back (recurring), after complete surgical removal (resection/ablation) of the affected tissue.

Atezolizumab and bevacizumab in combination is in clinical development for treating adults with high risk
of hepatocellular carcinoma (HCC) coming back (recurring), after complete surgical removal
(resection/ablation) of the affected tissue. HCC is the most common type of primary liver cancer, which
affects men more than women, and is more likely to develop the older a person gets.

Download PDF

Related posts

May 2022

April 2022

March 2022

March 2022

Feburary 2022

Feburary 2022

January 2021

September 2017

June 2017

April 2020

Get in touch

Register your details and one of our team will be in touch shortly.

Contact